
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes PLC is positioned for revenue growth through 2030, primarily driven by the acquisition of Lumryz, which is anticipated to generate annualized sales of approximately $265-$275 million by 2025 and has significant potential in niche markets. The positive outlook is bolstered by ongoing investments in the development of alixorexton and the continued growth of existing products like Aristada and Lybalvi, supporting expected earnings per share (EPS) growth. Additionally, the strategic acquisition of Lumryz enhances Alkermes’s commercial opportunities without adversely affecting its balance sheet, thereby strengthening both its short- and medium-term financial prospects.
Bears say
Alkermes PLC faces a challenging financial outlook due to anticipated declines in Lumryz sales following the loss of exclusivity in 2037, compounded by competition from multiple orexin 2 receptor agonists that may hinder overall growth. Furthermore, key risks such as the erosion of its royalty business, early-stage efficacy concerns regarding its orexin data, and significant exposure to Medicaid present additional pressures on earnings. Analysts have adjusted the company’s pricing targets downward, reflecting a more conservative EBITDA multiple and signifying skepticism regarding the long-term competitiveness and profitability of its core products.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares